Disc Medicine prices $450 million stock offering at $75/share

Disc Medicine Inc. priced an offering of 6 million shares of common stock at $75.00 each in a public offering, according to a press release on Tuesday. The biopharmaceutical company held a 30-day option to buy an extra 900,000 shares at the same price. The total expected gross proceeds from the offering were projected at $450 million, excluding underwriting fees, commissions, and other expenses.

The funds raised are meant to boost research and clinical trials for existing or new product candidates, support commercialization plans for bitopertin for specific conditions, and cover general corporate needs. Jefferies, Leerink Partners, Morgan Stanley, and Cantor are handling the underwriting, while LifeSci Capital, BMO Capital Markets, and H.C.

Wainwright & Co. are managing the process. The offering was part of a pre-existing shelf registration statement with the SEC since August 8, 2024. Disc Medicine specializes in developing treatments for hematologic diseases, focusing on vital biological processes related to red blood cells.